ReviewJournal of cellular and molecular medicine2009
Molecular drug targets in myeloproliferative neoplasms: mutant ABL1, JAK2, MPL, KIT, PDGFRA, PDGFRB and FGFR1.
Review in Journal of cellular and molecular medicine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 56 citations in OpenAlex.
- Exploring hematological alterations and genetics linked to SNV rs10974944 in myeloproliferative neoplasms among Amazon patients.Scientific reports · 2024Article
- Protein kinases: drug targets for immunological disorders.Nature reviews. Immunology · 2023Review
- Guideline on myeloproliferative neoplasms: Associacão Brasileira de Hematologia, Hemoterapia e Terapia Cellular: Project guidelines: Associação Médica Brasileira - 2019.Hematology, transfusion and cell therapy · 2019Article
- An optimized targeted Next-Generation Sequencing approach for sensitive detection of single nucleotide variants.Biomolecular detection and quantification · 2018Article
- Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy.OncoTargets and therapy · 2018Review
- Myeloproliferative neoplasm with eosinophilia and T-lymphoblastic lymphoma with ETV6-LYN gene fusion.Blood cancer journal · 2016Article
- [The study of 4 cases of myeloid neoplasm with t (5;12) (q33;p13) and the literatures review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2016Review
- The Burden of JAK2V617F Mutated Allele in Turkish Patients With Myeloproliferative Neoplasms.Journal of clinical medicine research · 2015Article
- JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.Cancer discovery · 2015Article
- Targeting self-renewal pathways in myeloid malignancies.Cell communication and signaling : CCS · 2013Article
- Quantitative threefold allele-specific PCR (QuanTAS-PCR) for highly sensitive JAK2 V617F mutant allele detection.BMC cancer · 2013Article
- ICON: Eosinophil Disorders.The World Allergy Organization journal · 2012Article
- Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field.Expert review of hematology · 2012Review
- Review
- Mutations in the transmembrane and juxtamembrane domains enhance IL27R transforming activity.The Biochemical journal · 2011Article
- Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia.Revista brasileira de hematologia e hemoterapia · 2011Article
- Part 4: pharmacogenetic variability in anticancer pharmacodynamic drug effects.The oncologist · 2011Review
- Frequency of heterozygous TET2 deletions in myeloproliferative neoplasms.Cancer management and research · 2010Article
- Cancer-associated myeloproliferation: old association, new therapeutic target.Mayo Clinic proceedings · 2010Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutically validated oncoproteins in myeloproliferative neoplasms (MPN) include BCR-ABL1 and rearranged PDGFR proteins. The latter are products of intra- (e.g. FIP1L1-PDGFRA) or inter-chromosomal (e.g. ETV6-PDGFRB) gene fusions. BCR-ABL1 is associated with chronic myelogenous leukaemia (CML) and mutant PDGFR with an MPN phenotype characterized by eosinophilia and in addition, in case of FIP1L1-PDGFRA, bone marrow mastocytosis. These genotype-phenotype associations have been effectively exploited in the development of highly accurate diagnostic assays and molecular targeted therapy. It is hoped that the same will happen in other MPN with specific genetic alterations: polycythemia vera (JAK2 V617F and other JAK2 mutations), essential thrombocythemia (JAK2V617F and MPL515 mutations), primary myelofibrosis (JAK2 V617F and MPL515 mutations), systemic mastocytosis (KITD816V and other KIT mutations) and stem cell leukaemia/lymphoma (ZNF198-FGFR1 and other FGFR1 fusion genes). The current review discusses the above listed mutant molecules in the context of their value as drug targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.